Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Moderate Buy” from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been given an average rating of “Moderate Buy” by the eleven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $131.30.

Several equities research analysts recently issued reports on the stock. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, April 30th. BTIG Research restated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 14th. HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a research report on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday. Finally, Barclays lifted their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, April 27th.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $61.85, for a total transaction of $432,950.00. Following the completion of the sale, the insider directly owned 33,377 shares in the company, valued at $2,064,367.45. This trade represents a 17.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the sale, the director owned 73,743 shares of the company’s stock, valued at approximately $4,348,624.71. This represents a 58.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 139,055 shares of company stock valued at $8,095,785 in the last ninety days. Insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Fairmount Funds Management LLC increased its position in shares of Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after acquiring an additional 333,340 shares during the last quarter. Viking Global Investors LP acquired a new stake in shares of Oruka Therapeutics during the third quarter valued at about $51,280,000. Deep Track Capital LP increased its position in shares of Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after acquiring an additional 735,983 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Oruka Therapeutics by 38.1% during the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after acquiring an additional 676,865 shares during the last quarter. Finally, RTW Investments LP increased its position in shares of Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after acquiring an additional 112,499 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Trading Up 8.9%

Oruka Therapeutics stock opened at $62.28 on Friday. Oruka Therapeutics has a 12-month low of $10.77 and a 12-month high of $91.00. The stock has a market cap of $3.76 billion, a P/E ratio of -32.10 and a beta of -0.26. The company has a 50-day moving average price of $61.10 and a 200 day moving average price of $42.47.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, analysts forecast that Oruka Therapeutics will post -2.05 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.